🌾 From ₹13,407 Cr to ₹16,602 Cr Profit: PI Industries FY25 EPS Hits ₹109.44 – Still the Safest Agri-Play?

🌾 From ₹13,407 Cr to ₹16,602 Cr Profit: PI Industries FY25 EPS Hits ₹109.44 – Still the Safest Agri-Play?

✅ At a Glance

MetricFY24FY25YoY Growth
Revenue from Ops₹13,407 Cr₹15,752 Cr🔼 +17.5%
Total Income₹14,845 Cr₹16,602 Cr🔼 +11.8%
Net Profit₹1,660 Cr₹3,305 Cr🚀 +99%
EPS (Basic)₹54.93₹109.44🚀 2x jump
CMP (19 May 2025)₹3,691.40
TTM P/E~33.7x

PI Industries just delivered an agri-powered earnings explosion — with EPS more than doubling in FY25. Holy chlorpyrifos!


🧪 About PI Industries

  • 🌱 Leader in custom synthesis & contract manufacturing (CSM) in agri and pharma
  • 🧪 Chemistry-led export model
  • 🇮🇳 India + international diversified biz
  • 📈 One of the cleanest mid-to-large caps with zero debt

If you like businesses where India does high-end tech + export scale, PI is your guy.


💰 FY25 Financials (Consolidated)

Line ItemFY25 (₹ Cr)
Revenue from Ops₹15,752 Cr
Total Expenses₹12,296 Cr
EBITDA (Est.)₹4,306 Cr
Net Profit (PAT)₹3,305 Cr
EPS (Basic)₹109.44
Cash from Ops₹1,413 Cr
Capex₹850 Cr
Free Cash Flow₹563 Cr ✅

The earnings are real. The chemistry is pure. The cash is flowing. But valuation?


🧮 Fair Value (FV) Estimate

  • EPS (TTM): ₹109.44
  • Fair P/E for high-quality export-led agri-pharma: 32x

👉 FV = ₹109.44 × 32 = ₹3,502

CMP = ₹3,691.40
➡️ Slightly overvalued (~5.4%) — but not in bubble territory.


🔍 Segment Breakdown

SegmentFY25 RevenueProfit (PBIT)
Agro Chemicals₹15,575 Cr₹2,391 Cr
Pharma₹2,151 Cr₹(304) Cr ❌

Agro rules the roost. Pharma still burning R&D cash — but once commercialized, this could be the next rerating trigger.


🏦 Balance Sheet Snapshot

ItemValue (₹ Cr)
Total Assets₹1,22,767 Cr
Cash & Bank₹5,923 Cr
Current Investments₹12,598 Cr
Receivables₹18,326 Cr
Inventories₹9,839 Cr
Equity₹1,01,570 Cr
Borrowings₹1,117 Cr
D/E Ratio0.01x 🔥

📦 High working capital, yes. But still runs debt-free and dividend-paying.


🧾 Cash Flow Game

  • OCF = ₹1,413 Cr
  • Capex = ₹850 Cr
  • FCF = ₹563 Cr
  • Dividend Paid = ₹227 Cr
  • Net Increase in Cash = -₹294 Cr (mostly capex-driven, not operating stress)

🧨 Risks

  • ❌ Pharma division bleeding: ₹(304) Cr loss
  • 💸 High capex phase may hit short-term FCF
  • 🌍 Export-heavy biz = FX risks
  • 👨‍🔬 Very dependent on new molecule launches

🧠 EduInvesting Take

“PI is not your average fertiliser uncle. This is agri’s Tesla, quietly building global tech contracts from India.”

The stock is not cheap — but it never gets cheap. If you’re looking for safe, clean, growth-led compounders — this is one of the last few left.

If pharma turns around? Add 25% to EPS in FY26.


🏁 Final Verdict

✔️ 2x profit jump
✔️ EPS ₹109.44
✔️ Virtually zero debt
✔️ Export tech moat
❌ Slightly overvalued
❌ Pharma still lagging

“If you want slow, non-flashy wealth creation with a chem-lab twist — PI Industries still deserves a place in your portfolio.”


Tags: PI Industries FY25 Results, EPS ₹109.44, best agrochem stocks India, PI share price, pharma turnaround PI, PI Industries analysis, eduinvesting coverage


Prashant Marathe

https://eduinvesting.in

Leave a Comment

Popular News

Disclaimer: Eduinvesting articles are for informational and educational purposes only. It is not investment advice, nor a recommendation to buy or sell any securities. Always do your own research or consult a SEBI-registered professional.

© 2025 EduInvesting.in – All rights reserved.
Finance news, market sarcasm, and stock market commentary delivered daily with zero jargon and maximum masala.

Built by humans. Powered by chai. Inspired by FOMO.

error: Content is protected !!
Scroll to Top